DNAprint Genomics (DNAG)

[stakddek]

Dr. Moskowitz at interesting conference, with interesting topic!


GenoMed CEO to Speak at Nucleic Acid World Summit: SARS, West Nile Virus, HIV to Be Discussed
July 21, 2003 09:31:00 AM ET


ST. LOUIS, July 21 /PRNewswire-FirstCall/ -- GenoMed, Inc. ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets: GMED), a St. Louis, Missouri-based medical genomics company, announced today that its CEO, David Moskowitz MD, has been asked to discuss the company's findings at the Nucleic Acid World Summit to be held in Boston, MA September 15-17, 2003.

The Nucleic Acid World Summit, "Transforming Cutting-Edge Science into Business," will focus on uses of RNA and DNA to understand and treat diseases, including viral scourges such as SARS, HIV, and West Nile virus. The Midwest is gearing up for another bout with West Nile virus later this month. SARS is likely to return on a global scale this fall. HIV is a long-standing global epidemic still not under control.

Dr. Moskowitz will address the conference on Tuesday, September 16. His talk is entitled "Improving the Odds of Therapeutic Efficacy: Blocking Angiotensin II."

Dr. Moskowitz said, "We've found that several viral diseases including HIV, TB, all cardiovascular disease, all cancers except prostate cancer, all autoimmune diseases, and several psychiatric diseases are associated with over-activity of angiotensin I-converting enzyme ('ACE'), and excess levels of its product, angiotensin II. An ACE inhibitor or angiotensin II receptor blocker ('ARB') should therefore increase the efficacy of any new treatment, including nucleic acid therapies."

Dr. Moskowitz continued, "One very promising therapy, small interfering double-stranded RNA (siRNA), may be especially useful in developing new anti-viral drugs against RNA viruses like the SARS coronavirus, West Nile virus, and HIV. Interfering RNA will be discussed extensively at this conference. But any anti-viral therapy will almost certainly be more effective when used as part of a drug combination. We believe ACE inhibitors and ARBs, acting on the host, will decrease the host's immune response to the SARS and West Nile viruses, decreasing mortality. Blocking angiotensin II should also decrease the ability of the HIV virus to reproduce. These drugs are available now. The result of combining our approach with anti-viral drugs could be an even more effective one-two knock-out punch against the disease."

Dr. Moskowitz ended by saying, "I'm happy to have been invited to this important conference. The invitation reflects the organizers' belief that our unifying view of human pathology will benefit the audience. For our part, we hope to profit by licensing our intellectual property to some of the attendees."

The Nucleic Acid World Summit is hosted by the Strategic Research Institute (www.srinstitute.com/NAWS). A number of major pharmaceutical companies and prominent biotechnology companies are scheduled to attend.

About GenoMed

GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) reported that the company has applied for patents based on its finding that the ACE gene is associated with many common diseases, including viral diseases such as HIV. The Company is currently recruiting volunteers for clinical trials including SARS, West Nile virus, and HIV. GenoMed has already proven that ACE is the key to preventing kidney failure due to diabetes and high blood pressure, and to delaying emphysema. GenoMed's treatment approach, which is patent-pending, is the cornerstone of the Company's Next Generation Disease Management(TM) program. If inhibiting angiotensin II can also be shown to limit disease from SARS, West Nile virus, and HIV, this too will be incorporated into the Company's Clinical Outcomes Improvement Program(TM) (COIP(TM)). Patients with diabetes, high blood pressure, or emphysema can already subscribe to GenoMed's COIP(TM) for $800 a year.

For questions, please contact Dave Moskowitz, tel. [phone], FAX [phone], email: [e-mail], or visit GenoMed at www.genomedics.com.

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) treatments, its function as a Next Generation Disease Management(TM) company, its Clinical Outcomes Improvement Program(TM), the effect of presenting at this professional conference, and the Company's research and development approach and business model. The words or phrases "would be," "will allow," "intends to," "will likely result," "promises," "anticipate," "are expected to," "will enable," "will continue," "potential", "estimate," "project," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) the success of its treatment approach, blocking angiotensin II, in viral diseases such as SARS, West Nile virus, and HIV; (b) whether the Company will have sufficient financing to conduct its research and development; (c) whether any licenses or strategic alliances will result from this conference; and (d) economic, regulatory, governmental, and technological factors which may affect the Company's business. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, the Company does not undertake, and specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

© 2003 PRNewswire